YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy
MediLink Therapeutics (Suzhou) Co., Ltd.
376 participants
Mar 17, 2026
INTERVENTIONAL
Conditions
Summary
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV infusion on day 1 of each 21 day cycle
1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
1000 or 1250 mg/m2, po, bid, from day 1 to Day 14 of each 21 day cycle
1000 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
10 mg/kg, IV infusion on day 1 and Day 8 of each 21 day cycle
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07461454